Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at Wedbush cut their Q3 2017 earnings per share estimates for Voyager Therapeutics in a report released on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.78) per share for the quarter, down from their prior estimate of ($0.67). Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2017 earnings at ($0.85) EPS, FY2017 earnings at ($3.01) EPS, Q1 2018 earnings at ($0.72) EPS, Q2 2018 earnings at ($0.73) EPS, Q3 2018 earnings at ($0.62) EPS, Q4 2018 earnings at ($0.63) EPS, FY2018 earnings at ($2.70) EPS, FY2019 earnings at ($2.58) EPS, FY2020 earnings at ($2.84) EPS and FY2021 earnings at ($2.13) EPS.

A number of other research firms have also weighed in on VYGR. TheStreet lowered shares of Voyager Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, April 21st. Stifel Nicolaus reissued a “buy” rating and set a $33.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. BidaskClub raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, ValuEngine lowered shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $25.33.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/q3-2017-eps-estimates-for-voyager-therapeutics-inc-decreased-by-wedbush-nasdaqvygr.html.

Shares of Voyager Therapeutics (VYGR) opened at 8.61 on Friday. The company has a 50-day moving average price of $9.25 and a 200 day moving average price of $10.64. The firm’s market capitalization is $231.16 million. Voyager Therapeutics has a one year low of $8.10 and a one year high of $18.25.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.11. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Rhumbline Advisers increased its position in Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after buying an additional 114 shares during the last quarter. Bessemer Group Inc. increased its position in Voyager Therapeutics by 148.1% in the second quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock valued at $402,000 after buying an additional 26,763 shares during the last quarter. Russell Investments Group Ltd. increased its position in Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares during the last quarter. Finally, Hershey Trust Co. increased its position in Voyager Therapeutics by 163.0% in the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares during the last quarter. 41.34% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.